ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Nov. 15, 2011--
Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) announced today that it
has been named the 8th Fastest Growing Company in New Jersey
according to NJBiz at the 2011 50 Fastest Growing Companies of NJ award
ceremony held in Somerset, NJ last night.
Marc D. Grodman, MD, CEO, commented: “We welcome the recognition of
NJBiz and the sponsoring organizations. We congratulate all the
companies that were recognized by NJBiz, and we especially congratulate
the loyal and valued employees of BioReference Laboratories who have
made BioReference such a special company.”
About BioReference Laboratories, Inc.
BRLI is the fourth largest full service laboratory in the United States
and the largest independent regional laboratory in the Northeastern
market, primarily a clinical testing laboratory servicing physician
offices with concentrations in the focused markets of esoteric testing,
molecular diagnostics, anatomical pathology, women’s health and
correctional health care. BRLI operates as a national oncology
laboratory as GenPath. Better science, superior technology and better
service have enabled GenPath to earn a reputation as one of the premier
hematopathology laboratories in the country. BRLI’s innovative
technology platform for sexually transmitted infections has enabled it
to expand as a national laboratory in the area of Women’s Health.
GeneDx, a wholly owned subsidiary, is the BRLI genetics laboratory and
is typically recognized as the leading laboratory for testing of rare
genetic diseases; GeneDx has now become a technology leader with
GenomeDx, based on a CGH array platform and its NextGen sequence
offerings that are currently offered in cardiology and will be offered
in the future in other disease specific areas.
Statements included in this release that are not historical in
nature, are intended to be, and are hereby identified as
“forward-looking statements”. Statements looking forward in time are
included in this release pursuant to the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. Such statements
involve known and unknown risks and uncertainties that may cause the
Company’s actual results in future periods to be materially different
from any future performance suggested herein.
www.bioreference.com
Source: Bio-Reference Laboratories, Inc.
Bio-Reference Laboratories, Inc.
Tara Mackay, (201) 791-2600
(201)
791-1941 (fax)
Investor Relations Coordinator
tmackay@bioreference.com
